Abstract 490P
Background
Glioblastoma multiforme (GBM) is the most aggressive and incurable form of the central nervous system’ tumors. One of the characteristics hindering the efficacy of treatments is the diffuse infiltration of glioma cells into the surrounding parenchyma. Glioma stem cells (GSC) have been reported as the putative population responsible for glioma invasion and recurrences. The identification of new therapeutic targets blocking glioma cells migration is therefore of primary importance. Since many studies have focused on the role of small GTP-binding proteins of the Rho GTPases family in cancer cells motility, we here aimed to identify effective inhibitors of Rac1 and Cdc42, from in silico to in vitro study.
Methods
Docking and molecular dynamics simulations were used to identify and validate binding sites on target proteins. Virtual screening simulations, based on the known structure of targets, were applied to select possible inhibitors of Rho GTPases. Selected compounds were tested, on U87 MG glioblastoma cells, to exclude cytotoxic effects and to evaluate their ability to interfere with cell migration, in vitro. Finally, we tested the ability of the more effective compounds to inhibit the in vitro migration of 18 patients derived-GSC.
Results
Binding sites on Rac1 and Cdc42 GTPases were identified and validated, and a small number (21) of possible inhibitors were selected for in vitro studies. 3 compounds had shown a reduction of U87 cells migration greater than 50%. Interestingly, GSCs showed a different migration behaviour among patients and different sensibility to the tested compounds.
Conclusions
Three molecules, selected on the basis of in silico studies predicting their binding to Rho GTPases, were able to efficiently interfere with the migration capability of glioma cells in vitro.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Udine.
Funding
Regione Autonoma Friuli Venezia Giulia - Italia, Ministero dell'Università e della Ricerca - Italia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16